How might treatment of ALK-positive non-small cell lung cancer change in the near future?

Affiliations

¹ a Medical Oncology , Santa Maria della Misericordia Hospital, Azienda Ospedaliera di Perugia , Perugia , Italy.
² b Department of Experimental Medicine, Division of Pathology and Histology , University of Perugia Medical School , Perugia , Italy.
³ c Department of Thoracic Surgery , Santa Maria della Misericordia Hospital, University of Perugia Medical School , Perugia , Italy.

Editorial

Giulio Metro et al. Expert Rev Anticancer Ther. 2016 Oct.

. 2016 Oct;16(10):997-9.

doi: 10.1080/14737140.2016.1226138. Epub 2016 Aug 25.

¹ a Medical Oncology , Santa Maria della Misericordia Hospital, Azienda Ospedaliera di Perugia , Perugia , Italy.
² b Department of Experimental Medicine, Division of Pathology and Histology , University of Perugia Medical School , Perugia , Italy.
³ c Department of Thoracic Surgery , Santa Maria della Misericordia Hospital, University of Perugia Medical School , Perugia , Italy.

No abstract available

Keywords: ALK; ALK-TKI; Alectinib; central nervous system metastases; ceritinib; crizotinib; lorlatinib; non-small cell lung cancer.

Publication types